Can infrastructure investments pressure Hims & Hers Health stock?

Traders Union
All News
Stocks
Hims & Hers Health drops 2.16% today

Highlights

Hims & Hers Health posted strong Q2 subscriber growth and expanded its branded weight loss and healthcare offerings.
Operating expenses and litigation costs are increasing, restraining near-term profitability for the company.
Shares of Hims & Hers trade below key moving averages with strong negative momentum and are expected to move within $26.29 to $30.01 over the next few days.

Profitability pressured as subscriber growth offsets rising costs

Hims & Hers Health reported second quarter results showing strong subscriber growth and broadening of its branded weight loss offerings, reflecting increased demand and expansion of its digital health service portfolio. Management, however, highlighted increased operating expenses and litigation costs as ongoing pressures, a factor which, according to Markets Financialcontent, is affecting the company's near-term profitability. The quarter was also marked by accelerated customer acquisition through new AI-powered services, infrastructure investments, entry into additional healthcare specialties, and the completed acquisition of Eucalyptus, collectively expanding the company's future growth avenues while weighing on margins in the short term.

Bearish momentum intensifies as technicals point to downside risk

On the technical front, HIMS/USD trades below the MA-20 ($29.17) and MA-50 ($30.28) on the hourly chart, and also stays under the MA-200 ($29.26) on the daily timeframe. The Ichimoku Kijun sits at $29.89 and acts as immediate resistance, while supports emerge near $26.29 and resistance near $30.01. Momentum readings remain weak: RSI stands at 29.3, Stoch RSI and CCI both show oversold conditions, and both MACD and ADX produce Sell signals. Bull/Bear Power is negative and the Awesome Oscillator confirms the ongoing downtrend.

Extended consolidation likely as low upside probability persists

In the short term, HIMS price is expected to consolidate within a typical volatility band between $26.29 and $30.01. The probability of an upward move is considered very low, while downside potential is high. Baseline expectation is for the stock to move sideways within this range. However, a break above $29.89 would open a bullish scenario, while decisive downside through $26.29 would signal renewed selling momentum.

Anton Kharitonov, expert at Traders Union, sees ongoing growth in Hims & Hers Health’s subscriber base and product expansion as supportive for long-term fundamentals. However, he believes persistent cost pressures and weak technical momentum continue to weigh on the stock in the near term. The chart setup signals heightened downside risk, with support at $26.29 and resistance at $30.01 remaining key. "Until HIMS reclaims $29.89 and shows renewed strength above trend resistance, I remain defensive and see little reason to pursue upside bets."

Earlier, analysts noted that Hims & Hers Health faced mounting technical and regulatory headwinds, which constrained its near-term recovery prospects. The latest operational updates reinforce these pressures, with additional downside risk now centered around the $26.29 support as a critical level to watch for renewed selling momentum.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.